CombiMatrix Corp (CBMX) Receives "Buy" Rating from Zacks Investment Research


's stock had its "buy" rating reissued by Zacks Investment Research in a research note issued on Sunday, MarketBeat Ratings reports. They currently have a $20.00 price target on the stock.



from Biotech News